Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APS TSE:BU NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$2.20+3.3%C$2.30C$1.02▼C$2.59C$5.61M-1.3788183,825 shs101 shsBUBurcon NutraScienceC$2.24+4.7%C$2.10C$1.51▼C$5.00C$28.43M2.8086996,005 shs5,518 shsSNSESensei Biotherapeutics$14.15+2.1%$22.60$5.86▼$36.76$18.59M-0.2553,599 shs219,729 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+3.29%-5.58%-5.58%-0.90%-7.56%BUBurcon NutraScience+4.67%+8.74%+12.00%+20.43%-14.50%SNSESensei Biotherapeutics+2.13%+12.00%-30.76%-53.67%+116.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$2.20+3.3%C$2.30C$1.02▼C$2.59C$5.61M-1.3788183,825 shs101 shsBUBurcon NutraScienceC$2.24+4.7%C$2.10C$1.51▼C$5.00C$28.43M2.8086996,005 shs5,518 shsSNSESensei Biotherapeutics$14.15+2.1%$22.60$5.86▼$36.76$18.59M-0.2553,599 shs219,729 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+3.29%-5.58%-5.58%-0.90%-7.56%BUBurcon NutraScience+4.67%+8.74%+12.00%+20.43%-14.50%SNSESensei Biotherapeutics+2.13%+12.00%-30.76%-53.67%+116.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 2.00HoldN/AN/ABUBurcon NutraScience 0.00N/AN/AN/ASNSESensei Biotherapeutics 2.43Hold$48.00239.34% UpsideCurrent Analyst Ratings BreakdownLatest BU, APS, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026SNSESensei Biotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.006/4/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/29/2026SNSESensei Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/28/2026SNSESensei Biotherapeutics Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$50.005/22/2026SNSESensei Biotherapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$55.004/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SNSESensei Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/20/2026SNSESensei Biotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.00(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.38 per share1.60C($13.59) per shareN/ABUBurcon NutraScienceC$1.48M19.19C$0.06 per share39.00C($0.20) per share-11.43SNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$10.41N/AN/AN/AN/A115.24%-136.29%N/ABUBurcon NutraScience-C$12.74M-C$1.07N/AN/AN/A-870.87%-630.53%-39.22%N/ASNSESensei Biotherapeutics-$21.08M-$142.72N/AN/AN/AN/A-83.59%-256.50%8/4/2026 (Estimated)Latest BU, APS, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/13/2026Q1 2026APSAptose BiosciencesN/A-C$4.16N/A-C$4.16N/AN/A3/31/2026Q4 2025APSAptose BiosciencesN/A-C$4.07N/A-C$4.07N/AN/A3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/ABUBurcon NutraScienceN/A4.45%N/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-98.740.555.41BUBurcon NutraScience-975.990.221.71SNSESensei BiotherapeuticsN/A14.3914.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences0.02%BUBurcon NutraScience0.05%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%BUBurcon NutraScience28.06%SNSESensei Biotherapeutics7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences312.55 millionN/ANot OptionableBUBurcon NutraScience2012.69 millionN/ANot OptionableSNSESensei Biotherapeutics401.34 million1.25 millionNot OptionableBU, APS, and SNSE HeadlinesRecent News About These CompaniesSensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives Average Rating of "Hold" from AnalystsJune 16 at 4:15 AM | americanbankingnews.comSensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in CancerJune 15 at 8:10 AM | businesswire.comSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2026 | businesswire.comMost and least shorted healthcare stocks with market cap up to $2B at the end of MayJune 3, 2026 | seekingalpha.comInsider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells 25,000 Shares of StockJune 2, 2026 | insidertrades.comCantor Fitzgerald initiates coverage of Sensei Biotherapeutics (SNSE) with overweight recommendationMay 30, 2026 | msn.comCitigroup initiates coverage of Sensei Biotherapeutics (SNSE) with buy recommendationMay 24, 2026 | msn.comSensei Biotherapeutics Updates 2026 Board Reconstitution PlansMay 22, 2026 | tipranks.comMillennium management reports $89k Sensei Biotherapeutics share salesMay 17, 2026 | investing.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in StockMay 16, 2026 | insidertrades.comSensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | businesswire.comSensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsMay 5, 2026 | finance.yahoo.comSensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerMay 5, 2026 | businesswire.comSensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00April 28, 2026 | msn.comSensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | businesswire.comSensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | businesswire.comSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2026 | businesswire.comMerger deal renews Faeth in Sensei; Piktor brightens, stock jumpsFebruary 18, 2026 | bioworld.comBSensei Biotherapeutics stock soars after Faeth Therapeutics acquisitionFebruary 18, 2026 | investing.comSensei Biotherapeutics stock soars 230% after Faeth dealFebruary 18, 2026 | msn.comMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20263 Infrastructure Stocks Fueling the Data Center Building BoomBy Dan Schmidt | May 18, 2026Why Applied Optoelectronics Stock May Be Near a Turning PointBy Thomas Hughes | May 18, 2026Zscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityBy Thomas Hughes | May 27, 2026BU, APS, and SNSE Company DescriptionsAptose Biosciences TSE:APSC$2.20 +0.07 (+3.29%) As of 06/16/2026 09:54 AM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Burcon NutraScience TSE:BUC$2.24 +0.10 (+4.67%) As of 06/16/2026 03:07 PM EasternBurcon is a global technology leader in the development of plant-based proteins. With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives. Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.Sensei Biotherapeutics NASDAQ:SNSE$14.14 +0.30 (+2.13%) Closing price 06/15/2026 07:54 PM EasternExtended Trading$14.14 0.00 (0.00%) As of 06/15/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
